|
| Variable | N (%) except as noted |
|
| Age, (years), mean ± SD | 28.1 ± 6.2 |
|
| Race/ethnicity | |
| White (non-Hispanic) | 11 (5.3%) |
| African-American (non-Hispanic) | 162 (78.3%) |
| Hispanic | 14 (6.8%) |
| Other | 20 (9.6%) |
|
| Year of delivery | |
| 2011-2012 | 83 (40.1%) |
| 2013-2014 | 71 (34.3%) |
| 2015-2106 | 53 (25.6%) |
|
| HIV Transmission Risk Factor | |
| Sexual | 122 (58.9%) |
| Perinatal | 22 (10.6%) |
| Other (IVDU, iatrogenic) | 5 (2.4%) |
| Unknown | 58 (28.0%) |
|
| HIV diagnosis during pregnancy | 47 (22.7%) |
|
| Time since HIV diagnosis (years), median (Q1, Q3) | 3 (1, 8) |
|
| In HIV care prior to pregnancy | 114 (55.3%) |
|
| On ART prior to pregnancy | 74 (36.8%) |
|
| Number of previous live births, median (Q1, Q3) | 1 (0, 2) |
|
| Number of prenatal care visits, median (Q1, Q3) | 9 (6, 11) |
|
| CD4 cell count at presentation (cells/mm3), mean ± SD | 412.9 ± 264.4 |
|
| Viral Loads | |
| Viral load <1000 c/mL during entire pregnancy | 85 (42.1%) |
| Viral load <200 c/mL during entire pregnancy | 62 (30.7%) |
| Viral load <1000 c/mL in third trimester | 150 (75.8%) |
| Viral load <200 c/mL in third trimester | 127 (64.1%) |
| Viral load <200 c/mL at delivery | 147 (71.0%) |
|
| ART interruption during pregnancy | 133 (64.9%) |
|
| Cesarean delivery | 99 (48.1%) |
|
| Perinatal HIV infection | 3 (1.5%) |
|
| Contraceptive plan at delivery (mutually exclusive)1 | |
| Tubal Ligation | 20 (9.8%) |
| Hormonal intrauterine device | 17 (8.3%) |
| Copper intrauterine device | 4 (2.0%) |
| Implant | 30 (14.6%) |
| DMPA | 62 (30.2%) |
| Oral contraceptives | 19 (9.3%) |
| Hormonal patch or ring | 3 (1.5%) |
| Condoms alone | 20 (9.8%) |
| None | 15 (7.3%) |
|
| Contraceptive provided at time of delivery | 126 (62.1%) |
|
| Attended 6 week obstetric postpartum appointment | 156 (76.4%) |
|
| Subsequent pregnancy | 44 (23.5%) |
|
| Postpartum transition to HIV Care | |
| Time (days), median (Q1, Q3) | 124 (70, 357) |
| <90 days | 73 (37.1%) |
| 90-180 days | 54 (27.4%) |
| > 180 days | 70 (35.5%) |
| No postpartum HIV visit | 10 (4.8%) |
|
| ART interruption after delivery | 97 (64.2%) |
|
| Change in ART regimen postpartum | 90 (59.2%) |
|
| Viral suppression2 | |
| 12 months postpartum | 76 (41.3%) |
| 24 months postpartum | 46 (30.1%) |
|
| Retention in HIV care2 | |
| 12 months postpartum | 86 (46.5%) |
| 24 months postpartum | 52 (34.0%) |
|
